ProKidney Corp. Files 8-K Report
Ticker: PROK · Form: 8-K · Filed: May 29, 2024 · CIK: 1850270
| Field | Detail |
|---|---|
| Company | Prokidney Corp. (PROK) |
| Form Type | 8-K |
| Filed Date | May 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-disclosure, financial-statements
TL;DR
ProKidney Corp. filed an 8-K, mostly for regulatory and financial updates. Formerly Social Capital Suvretta Holdings Corp. III.
AI Summary
On May 29, 2024, ProKidney Corp. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. ProKidney Corp. was formerly known as Social Capital Suvretta Holdings Corp. III until March 10, 2021.
Why It Matters
This filing provides updates on ProKidney Corp.'s regulatory disclosures and financial statements, which are important for investors to understand the company's current status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report detailing disclosures and financial statements, not indicating any immediate operational or financial distress.
Key Numbers
- 001-40560 — Commission File Number (Identifies the company's filing with the SEC)
- 98-1586514 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- PROKIDNEY CORP. (company) — Registrant
- Social Capital Suvretta Holdings Corp. III (company) — Former company name
- May 29, 2024 (date) — Date of report
- 2000 Frontis Plaza Blvd. Suite 250 (address) — Principal executive offices
- Winston-Salem, North Carolina (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing for ProKidney Corp.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was ProKidney Corp. formerly known by another name?
ProKidney Corp. was formerly known as Social Capital Suvretta Holdings Corp. III until March 10, 2021.
What is the address of ProKidney Corp.'s principal executive offices?
The address of ProKidney Corp.'s principal executive offices is 2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, North Carolina 27103.
What is ProKidney Corp.'s Commission File Number?
ProKidney Corp.'s Commission File Number is 001-40560.
On what date was this 8-K report filed?
This 8-K report was filed on May 29, 2024.
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-05-29 07:04:22
Key Financial Figures
- $0.0001 — ch registered Class A ordinary shares, $0.0001 par value per share PROK The Nasdaq
Filing Documents
- ef20030179_8k.htm (8-K) — 35KB
- ef20030179_ex99-1.htm (EX-99.1) — 21KB
- ef20030179_ex99-1slide1.jpg (GRAPHIC) — 147KB
- ef20030179_ex99-1slide2.jpg (GRAPHIC) — 255KB
- ef20030179_ex99-1slide3.jpg (GRAPHIC) — 112KB
- ef20030179_ex99-1slide4.jpg (GRAPHIC) — 85KB
- ef20030179_ex99-1slide5.jpg (GRAPHIC) — 123KB
- ef20030179_ex99-1slide6.jpg (GRAPHIC) — 97KB
- ef20030179_ex99-1slide7.jpg (GRAPHIC) — 107KB
- ef20030179_ex99-1slide8.jpg (GRAPHIC) — 114KB
- ef20030179_ex99-1slide9.jpg (GRAPHIC) — 137KB
- ef20030179_ex99-1slide10.jpg (GRAPHIC) — 98KB
- 0001140361-24-027808.txt ( ) — 1956KB
- prok-20240529.xsd (EX-101.SCH) — 4KB
- prok-20240529_lab.xml (EX-101.LAB) — 22KB
- prok-20240529_pre.xml (EX-101.PRE) — 16KB
- ef20030179_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. ProKidney Corp. (the "Company") provided investors with a presentation setting forth final data from the Company's Phase 2 RMCL-002 clinical trial (the "Presentation"). The Presentation is available on the Company's website at https://investors.prokidney.com/news-events/events-and-presentations. The Presentation is also attached hereto as Exhibit 99.1. The information in this report is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in Items 7.01 and 9.01 of this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The exhibits filed as part of this Current Report on Form 8-K are listed in the index to exhibits immediately preceding the signature page to this Current Report on Form 8-K, which index to exhibits is incorporated herein by reference. Exhibit No. Description 99.1 Investor Presentation 104 Cover Page Interactive Data File (embedded within Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROKIDNEY CORP. Date: May 29, 2024 By: /s/ Todd Girolamo Todd Girolamo Chief Legal Officer